Literature DB >> 22300396

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Elin Svensson1, Jan-Stefan van der Walt, Karen I Barnes, Karen Cohen, Tamara Kredo, Alwin Huitema, Jean B Nachega, Mats O Karlsson, Paolo Denti.   

Abstract

AIMS: To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example.
METHODS: Data from three studies including 115 human immunodeficiency virus-infected South African adults were used. Patients were on antiretroviral therapy regimens including 200 mg nevirapine twice daily and sampled at steady state. A development process was suggested, implemented in NONMEM7 and the final model evaluated with an external data set.
RESULTS: A stepwise approach proved efficient. Model development started with the intensively sampled data. Data were added sequentially, using visual predictive checks for inspecting their compatibility with the existing model. Covariate exploration was carried out, and auxiliary regression models were designed for imputation of missing covariates. Nevirapine pharmacokinetics was described by a one-compartment model with absorption through two transit compartments. Body size was accounted for using allometric scaling. The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter. Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h. Concomitant antitubercular treatment including rifampicin typically decreased bioavailability by 39%, with significant between-subject variability. Visual predictive checks of external validation data indicated good predictive performance.
CONCLUSIONS: The development strategy succeeded in integrating data from different sources to produce a model with robust parameter estimates. This work paves the way for the creation of a nevirapine mega-model, including additional data from numerous diverse sources.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300396      PMCID: PMC3477348          DOI: 10.1111/j.1365-2125.2012.04205.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  50 in total

1.  Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.

Authors:  M J Lamson; J P Sabo; T R MacGregor; J W Pav; L Rowland; A Hawi; M Cappola; P Robinson
Journal:  Biopharm Drug Dispos       Date:  1999-09       Impact factor: 1.627

2.  Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Authors:  Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Comput Methods Programs Biomed       Date:  2010-06-02       Impact factor: 5.428

3.  Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.

Authors:  E Dailly; F Raffi; P Perré; J Martin; G Deslandes; P Jolliet
Journal:  HIV Med       Date:  2009-05-21       Impact factor: 3.180

4.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

5.  Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.

Authors:  Thorsten Lehr; Jing Yuan; David Hall; Heike Zimdahl-Gelling; Hans Guenter Schaefer; Alexander Staab; Thomas R MacGregor; Supriya Jayadev
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

6.  Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Authors:  Monidarin Chou; Julie Bertrand; Olivier Segeral; Céline Verstuyft; Laurence Borand; Emmanuelle Comets; Clotilde Le Tiec; Laurent Becquemont; Vara Ouk; France Mentre; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

7.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.

Authors:  Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

8.  Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

Authors:  Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens
Journal:  AIDS Res Ther       Date:  2010-07-14       Impact factor: 2.250

9.  Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Authors:  Karen Cohen; Alison Grant; Collet Dandara; Helen McIlleron; Lindiwe Pemba; Katherine Fielding; Salome Charalombous; Gavin Churchyard; Peter Smith; Gary Maartens
Journal:  Antivir Ther       Date:  2009

10.  Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Authors:  Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

View more
  14 in total

1.  Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.

Authors:  Stein Schalkwijk; Rob Ter Heine; Angela Colbers; Edmund Capparelli; Brookie M Best; Tim R Cressey; Rick Greupink; Frans G M Russel; José Moltó; Mark Mirochnick; Mats O Karlsson; David M Burger
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

2.  Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-27       Impact factor: 2.745

3.  Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.

Authors:  Elisabet Størset; Nick Holford; Stefanie Hennig; Troels K Bergmann; Stein Bergan; Sara Bremer; Anders Åsberg; Karsten Midtvedt; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

4.  Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Authors:  Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

5.  Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.

Authors:  Miné de Kock; Joel Tarning; Lesley Workman; Elizabeth N Allen; Mamadou M Tekete; Abdoulaye A Djimde; David J Bell; Steve A Ward; Karen I Barnes; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.

Authors:  Emmanuel Chigutsa; Siva Rama Prasad Kambhampati; Amanda Karen Sykes; Maria M Posada; Jan-Stefan van der Walt; P Kellie Turner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-08-13

7.  A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.

Authors:  Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2021-02-22       Impact factor: 6.447

8.  Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications.

Authors:  Tjokosela Tikiso; Helen McIlleron; David Burger; Diana Gibb; Helena Rabie; Janice Lee; Marc Lallemant; Mark F Cotton; Moherndran Archary; Stefanie Hennig; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2021-08-12       Impact factor: 3.716

9.  The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Authors:  Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Adeniyi Olagunju; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Andrew Owen; A Sarah Walker; Diana M Gibb; Helen McIlleron; David Burger; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2016-04-25       Impact factor: 4.335

10.  Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Authors:  Ali Mohamed Ali; Melissa A Penny; Thomas A Smith; Lesley Workman; Philip Sasi; George O Adjei; Francesca Aweeka; Jean-René Kiechel; Vincent Jullien; Marcus J Rijken; Rose McGready; Julia Mwesigwa; Kim Kristensen; Kasia Stepniewska; Joel Tarning; Karen I Barnes; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.